The REWIND trial
The REWIND trial was a cardiovascular outcomes trial involving dulaglutide, but was notable for having recruited a majority of people (approximately 70%) who did not have overt cardiovascular disease.
The investigators found a significant reduction in cardiovascular risk, irrespective of whether participants had established cardiovascular disease, suggesting that glucagon-like peptide-1 receptor agonists may be cardioprotective even in patients who have not yet had a clinical event. They also found a significant reduction in the risk for renal outcomes, in an exploratory analysis.
The REWIND investigators will present data on the effects of dulaglutide on stroke outcomes at 55th EASD Annual Meeting (EASD 2019):
Unique features and findings of the long-term REWIND (Researching cardiovascular Events with a Weekly INcretin in Diabetes) trial
Thursday, September 19, 12:00–13:00. Vilanova Hall, Fira Barcelona Gran Via, Spain.
Session Chair: L. Rydén, Sweden
- Effect of dulaglutide on serious health outcomes. H. C. Gerstein, Canada
- New findings from the REWIND trial. M. C. Riddle, USA
What our Editorial Board said:
John Wilding discusses how the results of the REWIND study add to our knowledge of the effects of the glucagon-like peptide-1 receptor agonist class in people with varying degrees of cardiovascular risk (3:37).